Skip to content

Depression research published in 2024

Page 3 of 26: studies 41 to 60 of 512, newest first. Back to the depression overview

Studies

Efficacy of the "7mind"-app as intervention to prevent postpartum depression in a low-risk sample group.

Archives of gynecology and obstetrics December 1, 2024 Laura Hahn, Marilena Thomann, Eva-Maria Dreyer et al. 1 citation

Postpartum depression (PPD) is a severe complication in the postpartum period and equals a major depression occurring in the first weeks after delivery. During the COVID-19 pandemic, an increased incidence of PPD was observed. For this reason, we conducted an intervention study to test the effectiveness of the "7mind"-app, an app-based mindfulness training program, in the prevention of PPD. For...

DOI: 10.1007/s00404-024-07851-1 (opens in new tab) Full text (opens in new tab) 7 mind-app; e-health Mindfulness-based intervention Ppd Postpartum depression +1

Effectiveness of Mindfulness on Student Anxiety and Depression During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.

Nursing & health sciences December 1, 2024 Gst Kade Adi Widyas Pranata, Apryadno Jose Al Freadman Koa, Ying-Ju Chang 2 citations

Anxiety and depression are the most common psychological issues experienced by students during the COVID-19 pandemic. Mindfulness has been suggested as a potential solution to these issues; however, limited studies have evaluated its effectiveness. This study aimed to synthesize experimental studies that measure the effectiveness of mindfulness in reducing student anxiety and depression during...

An Online Mindfulness-based Intervention Decreases Stress, Anxiety, and Depression in Indian Healthcare Providers during the COVID-19 Pandemic: A Prospective Randomized Controlled Study.

Journal of the Association of Physicians of India December 1, 2024 Anirban Pal, Purnava Mukhopadhyay, Nidhi D Pal 1 citation

The coronavirus disease 2019 (COVID-19) pandemic contributed enormously to the psychosocial distress of Indian healthcare providers. The mental well-being of the healthcare community remains an underappreciated priority in India. The primary objective was to observe the results of an online brief mindfulness-based intervention on stress, anxiety, and depression, and the secondary objective was...

Role of Mindfulness in the Effects of Organizational Culture on Depression in Korean Physical Therapists.

Safety and health at work December 1, 2024 Jong-Hyun Lee, Jinwon Lee, Jaejin Hwang et al. 3 citations

The study aimed to investigate whether mindfulness could mitigate the impact of job and interpersonal demands arising from stressful organizational cultures in predicting depression during the COVID-19 pandemic. A total of 280 Korean physical therapists participated in this study. To verify the mediated moderation model, this study implemented an SPSS 26.0 PROCESS Macro (v.3.5) that was based...

The effect of mindfulness-based cognitive therapy on PTSD and depression symptoms in trauma-exposed black adults: Pilot randomized controlled trial results.

Journal of Mood and Anxiety Disorders December 1, 2024 Malin Au, Rebecca Lipschutz, Yara Mekawi et al. 4 citations

Low-income, urban-dwelling Black adults are disproportionately affected by traumatic experiences, post-traumatic stress disorder (PTSD), and depression and encounter inequities in treatment access. In addition to the benefits Mindfulness-Based Cognitive Therapy (MBCT) for depression, there is preliminary evidence of successful symptom reduction in PTSD via MBCT across two prior pilot studies in...

DOI: 10.1016/j.xjmad.2024.100092 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mindfulness-based cognitive therapy Posttraumatic stress disorder

Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.

Molecular Psychiatry December 1, 2024 Chloe E Page, C Neill Epperson, Andrew M Novick et al. 54 citations

The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despite insufficient supporting evidence. To combat rising mental health crises and eroding public trust in science and medicine, researchers and clinicians must be able to communicate to patients and the public an updated framework of MDD: one that is (1)...

Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice.

IBRO Neuroscience Reports December 1, 2024 Gabriela N Vaz, Flávia C Turcato, Isabel A V Lima et al.

About one-third of major depressive disorder (MDD) patients demonstrate unresponsiveness to classic antidepressants, and even the clinical efficacy of fast-acting drugs such as ketamine varies significantly among patients with treatment-resistant depression. Nevertheless, the lack of suitable animal models that mimic a possible ketamine-resistant phenotype challenges the understanding of...

Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.

Pharmacological Reports December 1, 2024 Aleksander Kwaśny, Wiesław Jerzy Cubała, Adam Włodarczyk et al. 2 citations

This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration. This is a post-hoc analysis of a naturalistic observational study, which enrolled 28 inpatients with treatment-resistant major depressive disorder and analyzed self-reported sleep changes (items 1-4; 'insomnia', 'nighttime restlessness', 'early...

Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.

Psychiatry and Clinical Neurosciences December 1, 2024 Yohei Ohtani, Hideaki Tani, Kie Nomoto-Takahashi et al. 13 citations

Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. We aimed to evaluate the efficacy and safety of intravenous ketamine in Japanese patients with TRD. In this double-blind randomized placebo-controlled trial, 34 Japanese patients with TRD were...

The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder.

Pharmacological Reports December 1, 2024 Julia Kwaśna, Wiesław Jerzy Cubała, Aleksander Kwaśny et al. 4 citations

Emerging evidence indicates that intravenous ketamine is effective in managing treatment-resistant unipolar and bipolar depression. Clinical studies highlight its favorable efficacy, safety, and tolerability profile within a dosage range of 0.5-1.0 mg/kg based on actual body weight. However, data on alternative dosage calculation methods, particularly in relation to body mass index (BMI) and...

Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.

Drugs - real world outcomes December 1, 2024 Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny 3 citations

Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management strategies to achieve functional recovery. This observational study aimed to evaluate the impact of ketamine infusions on depressive symptoms in patients with bipolar disorder who continued their baseline psychotropic and chronic somatic treatments....

DOI: 10.1007/s40801-024-00453-y (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar depression Treatment resistance Psychiatric medicine +1

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.

CNS Drugs December 1, 2024 Ruyun Liu, Ning Liu, Lin Ma et al. 5 citations

Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhibit limitations such as delayed onset of action and a high incidence of adverse reactions. Therefore, there is a pressing need to develop antidepressants that exhibit enhanced efficacy and safety. The N-methyl-D-aspartate receptor (NMDAR), a...

DOI: 10.1007/s40263-024-01123-x (opens in new tab) Full text (opens in new tab) Mental-health Depression-treatment Drug-development Brain-research

Molecular signature underlying (R)-ketamine rapid antidepressant response on anhedonic-like behavior induced by sustained exposure to stress.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Ellen Scotton, Paola Rampelotto Ziani, Renata Luiza Boff Wilges et al. 1 citation

Anhedonia induced by sustained stress exposure is a hallmark symptom of major depressive disorder (MDD) and in rodents, it can be accessed through the sucrose preference test (SPT). (R)-ketamine is a fast-acting antidepressant with less detrimental side effects and abuse liability compared to racemic ketamine. The present study combined high-throughput proteomics and network analysis to...

DOI: 10.1016/j.pbb.2024.173882 (opens in new tab) Full text (opens in new tab) Major depressive disorder R-ketamine treatment response Anhedonic-like behavior Molecular targets +6

Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.

Expert Opinion on Pharmacotherapy December 1, 2024 Millie C Kirchberg, Claire Pinson, Guido K W Frank 9 citations

Anorexia nervosa (AN) has one of the highest mortality rates of all mental illnesses. No approved pharmacological treatments exist for AN, but novel neurobiological targets show promise. Studies show that in individuals with AN, there are alterations in brain neurotransmitter signaling, alongside associated mental rigidity and comorbid anxiety and depression. Available and new therapies could...

Intravenous ketamine infusions in patients with depression and Epilepsy: Case series.

Journal of Clinical Neuroscience December 1, 2024 Mariusz Stanisław Wiglusz, Zuzanna Chmielewska, Wiesław Jerzy Cubała 1 citation

Mood disorders affect approximately one-third of individuals with epilepsy, posing an increased risk of suicide. There is an unquestionable need for more effective antidepressant treatment in this group of patients. This study explores the safety and tolerability of low-dose intravenous ketamine in six patients with comorbid depression and epilepsy. This report is limited to the post-hoc...

DOI: 10.1016/j.jocn.2024.110908 (opens in new tab) Full text (opens in new tab) Case report Intravenous #depression-treatment depression therapy Mood disorder treatment +6

Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research December 1, 2024 Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh et al. 13 citations

A large number of people worldwide grapple with Major Depressive Disorder (MDD), and a significant portion of them confront resistance to conventional antidepressant treatments. Esketamine, an innovative intervention, has garnered attention due to its rapid-acting antidepressant effects. This meta-analysis aimed to evaluate the efficacy and safety of esketamine in individuals with MDD and...

Splenic γδ T cells mediate antidepressant and prophylactic actions of arketamine in lipopolysaccharide-induced depression in mice.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Guilin Liu, Li Ma, Akemi Sakamoto et al. 4 citations

Arketamine, the (R)-enantiomer of ketamine, exhibits both therapeutic and sustained prophylactic effects in an inflammation-driven model of depression, although the precise mechanisms remain elusive. Given the involvement of γδ T cells in inflammatory processes, this study explored their role in the effects of arketamine. To assess therapeutic outcomes, mice received lipopolysaccharide (LPS:1.0...

DOI: 10.1016/j.pbb.2024.173906 (opens in new tab) Full text (opens in new tab) Arketamine Prophylactic Spleen Antidepressants antidepressant medication +8

Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.

Psychiatry Research December 1, 2024 Shampa Maji, Archana Mishra, Debadatta Mohapatra et al. 5 citations

Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorder (MDD). Following the success of ketamine, more clinical research on NMDA antagonists is needed for a safe and long-term therapy in MDD. Hence, this study was conducted to evaluate the efficacy and safety of adjunct dextromethorphan to SSRIs in MDD....

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.

The International Journal of Neuropsychopharmacology December 1, 2024 Craig Chepke, Richard C. Shelton, Gerard Sanacora et al. 7 citations

Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults and for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. No adverse events (AEs) of respiratory depression were reported in ESK phase 3 clinical trials; however, postmarketing...

DOI: 10.1093/ijnp/pyae058 (opens in new tab) Full text (opens in new tab) Esketamine nasal spray Respiratory depression Depression treatment Esketamine therapy +3

Navigating Treatment-Resistant Major Depressive Disorder With Suicidal Ideation: Exploring the Efficacy of Spravato (Esketamine) in an 86-Year-Old Male.

Cureus December 1, 2024 Aarman P Jivraj, Katherine A Heimer, Christopher J Wukovits et al. 1 citation

This case study examines the novel application of Spravato (intranasal esketamine) to address treatment-resistant Major Depressive Disorder (MDD) in an 86-year-old patient. Notably, this represents one of the oldest documented individuals to be administered intranasal esketamine for a diagnosis of Treatment-Resistant Depression (TRD) alongside suicidal ideation. This case study contributes to...